Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Eline van Diest"'
Autor:
Zsolt Sebestyen, Jürgen Kuball, Shuang Li, Eric Eldering, Monique C Minnema, Eline van Diest, Sarah Grabherr, Thomas Kimman, Anne Slomp, Anne Martens, Jan Meeldijk, Niels Bovenschen, Victor Peperzak
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss 3 (2023)
Background Initial clinical responses with gene engineered chimeric antigen receptor (CAR) T cells in cancer patients are highly encouraging; however, primary resistance and also relapse may prevent durable remission in a substantial part of the pati
Externí odkaz:
https://doaj.org/article/f0db432c403249b0a8207df36512c064
Autor:
Eline van Diest, Mara J. T. Nicolasen, Lovro Kramer, Jiali Zheng, Patricia Hernández-López, Dennis X. Beringer, Jürgen Kuball
Publikováno v:
Frontiers in Immunology, Vol 13 (2023)
IntroductionWe have recently developed a novel T cell engager concept by utilizing γ9δ2TCR as tumor targeting domain, named gamma delta TCR anti-CD3 bispecific molecule (GAB), targeting the phosphoantigen-dependent orchestration of BTN2A1 and BTN3A
Externí odkaz:
https://doaj.org/article/232d0130c39246d1ac4f3b33e792c6f8
Autor:
Tassilo L. A. Wachsmann, Anne K. Wouters, Dennis F. G. Remst, Renate S. Hagedoorn, Miranda H. Meeuwsen, Eline van Diest, Jeanette Leusen, Jürgen Kuball, J. H. Frederik Falkenburg, Mirjam H. M. Heemskerk
Publikováno v:
OncoImmunology, Vol 11, Iss 1 (2022)
Chimeric antigen receptor (CAR) T cell therapies have resulted in profound clinical responses in the treatment of CD19-positive hematological malignancies, but a significant proportion of patients do not respond or relapse eventually. As an alternati
Externí odkaz:
https://doaj.org/article/61bf7803b46c4bb0b949c96cdcd43b7e
Autor:
Guido J.J. Kierkels, Eline van Diest, Patricia Hernández-López, Wouter Scheper, Anja C.M. de Bruin, Elselien Frijlink, Tineke Aarts-Riemens, Sanne F.J. van Dooremalen, Dennis X. Beringer, Rimke Oostvogels, Lovro Kramer, Trudy Straetemans, Wolfgang Uckert, Zsolt Sebestyén, Jürgen Kuball
Publikováno v:
Molecular Therapy: Methods & Clinical Development, Vol 22, Iss , Pp 388-400 (2021)
T cell engineering strategies offer cures to patients and have entered clinical practice with chimeric antibody-based receptors; αβT cell receptor (αβTCR)-based strategies are, however, lagging behind. To allow a more rapid and successful transla
Externí odkaz:
https://doaj.org/article/41ed21d53f8d4312b23072193b1bc35e
Autor:
Inez Johanna, Trudy Straetemans, Sabine Heijhuurs, Zsolt Sebestyen, Jürgen Kuball, Eline van Diest, Patricia Hernández López, Angelo D Meringa, Anna Vyborova, Froso Karaiskaki, Jan Gumathi Bormin, Sanne van Dooremalen, Mara J T Nicolasen, Lucrezia C D E Gatti, Dennis X Beringer
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 11 (2021)
Externí odkaz:
https://doaj.org/article/de666a740e2143a1a08f52a3ccd29c36
Autor:
Anke Janssen, Eline van Diest, Anna Vyborova, Lenneke Schrier, Anke Bruns, Zsolt Sebestyen, Trudy Straetemans, Moniek de Witte, Jürgen Kuball
Publikováno v:
Viruses, Vol 14, Iss 1, p 117 (2022)
In the complex interplay between inflammation and graft-versus-host disease (GVHD) after allogeneic stem cell transplantation (allo-HSCT), viral reactivations are often observed and cause substantial morbidity and mortality. As toxicity after allo-HS
Externí odkaz:
https://doaj.org/article/2322f1aa54704b9db02bce34b41fad08
Autor:
Leo Hanke, Kevin E. Knockenhauer, R. Camille Brewer, Eline van Diest, Florian I. Schmidt, Thomas U. Schwartz, Hidde L. Ploegh
Publikováno v:
mBio, Vol 7, Iss 6 (2016)
ABSTRACT Alpaca-derived single-domain antibody fragments (VHHs) that target the influenza A virus nucleoprotein (NP) can protect cells from infection when expressed in the cytosol. We found that one such VHH, αNP-VHH1, exhibits antiviral activity si
Externí odkaz:
https://doaj.org/article/e70c51221c44493787a3471757f91761
Autor:
Trudy Straetemans, Anja C.M. de Bruin, Rimke Oostvogels, Wolfgang Uckert, Jürgen Kuball, Sanne van Dooremalen, Tineke Aarts-Riemens, Lovro Kramer, Patricia Hernández-López, Wouter Scheper, Elselien Frijlink, Zsolt Sebestyén, Dennis X. Beringer, Eline van Diest, Guido J. J. Kierkels
Publikováno v:
Molecular Therapy. Methods & Clinical Development
Molecular Therapy: Methods & Clinical Development, Vol 22, Iss, Pp 388-400 (2021)
Molecular Therapy: Methods & Clinical Development, Vol 22, Iss, Pp 388-400 (2021)
T cell engineering strategies offer cures to patients and have entered clinical practice with chimeric antibody-based receptors; αβT cell receptor (αβTCR)-based strategies are, however, lagging behind. To allow a more rapid and successful transla
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::677b56a73c442d2e3fe51c15977b4ccc
http://edoc.mdc-berlin.de/20417/1/20417oa.pdf
http://edoc.mdc-berlin.de/20417/1/20417oa.pdf
Autor:
Sabine Heijhuurs, Eline van Diest, Trudy Straetemans, Patricia Hernández-López, Jürgen Kuball, Inez Johanna, Dennis X. Beringer, Zsolt Sebestyén
Despite the ability of {gamma}{delta}T cells to mediate tumor killing independently of MHC recognition, all the clinical trials that have been carried out using these cells showed low response rate in patients, in part due to its poor proliferation a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3b1ada670e7e76cdbd4be60be51937ab
https://doi.org/10.1101/2021.01.06.424553
https://doi.org/10.1101/2021.01.06.424553
Autor:
Eline van Diest, Froso Karaiskaki, Dennis X. Beringer, Sanne van Dooremalen, Jürgen Kuball, Zsolt Sebestyén, Jan Gumathi Bormin, Lucrezia C D E Gatti, Trudy Straetemans, Inez Johanna, Anna Vyborova, Sabine Heijhuurs, Patricia Hernández López, Mara J T Nicolasen, Angelo D Meringa
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 11 (2021)
Journal for Immunotherapy of Cancer
Journal for Immunotherapy of Cancer
Backgroundγ9δ2 T cells hold great promise as cancer therapeutics because of their unique capability of reacting to metabolic changes with tumor cells. However, it has proven very difficult to translate this promise into clinical success.MethodsIn o